Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Leiomyosarcoma × dinutuximab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 8 Osteosarcoma 3 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Neoplasm, Residual 1 Medulloblastoma 1 Leiomyosarcoma 1 Glioma 1 Glioblastoma 1 Ganglioneuroblastoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1

Interventions

Doxorubicin 13 Ifosfamide 9 Gemcitabine 8 Trabectedin 7 Radiotherapy 7 Docetaxel 5 Dacarbazine 5 pazopanib 3 Sunitinib 3 Sorafenib 3 Nivolumab 3 Filgrastim 3 pegfilgrastim 2 eribulin 2 cixutumumab 2 belinostat 2 Radiotherapy, Conformal 2 Imatinib Mesylate 2 Chemotherapy, Adjuvant 2 Bevacizumab 2 tremelimumab 1 temsirolimus 1 soblidotin 1 selinexor 1 sargramostim 1 saracatinib 1 rubitecan 1 romidepsin 1 ridaforolimus 1 reolysin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05080790 2025-08-17

DiTuSarc

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Completed

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡